Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.42 +2.2%	$16.48	$9.57 ▼ $27.34	$2.27B	0.94	2.03 million shs	2.81 million shs
KNSA Kiniksa Pharmaceuticals International	$32.15 -2.9%	$28.95	$17.82 ▼ $33.98	$2.35B	0.14	703,396 shs	675,329 shs
PRME Prime Medicine	$3.79 +3.0%	$3.10	$1.11 ▼ $5.17	$509.74M	2.39	2.47 million shs	3.59 million shs
RXRX Recursion Pharmaceuticals	$5.36 -0.9%	$5.40	$3.79 ▼ $12.36	$2.18B	0.93	29.20 million shs	11.99 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+3.08%	-12.94%	+26.21%	-34.32%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.53%	+11.05%	+23.23%	+33.90%
PRME Prime Medicine	0.00%	-6.19%	-19.19%	+191.54%	-13.86%
RXRX Recursion Pharmaceuticals	0.00%	-5.63%	-6.29%	+23.79%	-15.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	4.1705 of 5 stars	4.4	2.0	3.4	2.9	1.7	0.0
KNSA Kiniksa Pharmaceuticals International	3.4267 of 5 stars	3.5	3.0	0.0	3.7	3.3	0.6
PRME Prime Medicine	3.6474 of 5 stars	4.4	1.0	0.0	2.5	5.0	0.6
RXRX Recursion Pharmaceuticals	2.0386 of 5 stars	3.2	2.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.89	Moderate Buy	$43.14	162.75% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	28.05% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	135.27% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	30.60% Upside

Current Analyst Ratings Breakdown

Latest PRME, KNSA, RXRX, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	638.76	N/A	N/A	$1.54 per share	10.66
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.54	N/A	N/A	$6.78 per share	4.74
PRME Prime Medicine	$3.85M	132.54	N/A	N/A	$1.37 per share	2.77
RXRX Recursion Pharmaceuticals	$58.84M	37.03	N/A	N/A	$2.26 per share	2.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	23.70	N/A	-47.81%	-11.95%	N/A
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	803.95	128.60	N/A	0.90%	1.05%	0.80%	N/A
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	N/A

Latest PRME, KNSA, RXRX, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	38.15%	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
PRME Prime Medicine	N/A	6.50	6.50
RXRX Recursion Pharmaceuticals	0.02	3.58	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KNSA Kiniksa Pharmaceuticals International	53.95%
PRME Prime Medicine	70.37%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
KNSA Kiniksa Pharmaceuticals International	53.48%
PRME Prime Medicine	22.74%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
PRME Prime Medicine	234	134.50 million	100.38 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

PRME, KNSA, RXRX, and ARWR Headlines

Recent News About These Companies

Head to Head Comparison: Recursion Pharmaceuticals (NASDAQ:RXRX) & Addex Therapeutics (NASDAQ:ADXN)

1 hour ago | americanbankingnews.com

Leerink Partnrs Has Positive Outlook of RXRX Q3 Earnings

1 hour ago | americanbankingnews.com

Equities Analysts Set Expectations for RXRX Q3 Earnings

August 9 at 8:08 AM | marketbeat.com

Headlands Technologies LLC Buys 76,536 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 9 at 5:54 AM | marketbeat.com

Is Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?

August 8 at 11:31 AM | 247wallst.com

Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

August 6, 2025 | finance.yahoo.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript

August 6, 2025 | msn.com

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

August 6, 2025 | zacks.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Expectations By $0.06 EPS

August 6, 2025 | marketbeat.com

Recursion (RXRX) Q2 Revenue Jumps 33%

August 6, 2025 | theglobeandmail.com

5RXRX : Recursion Pharmaceuticals Earnings Preview

August 6, 2025 | benzinga.com

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

August 6, 2025 | msn.com

Why Recursion Pharmaceuticals Stock Tanked on Tuesday

August 5, 2025 | fool.com

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2025 | zacks.com

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025 | globenewswire.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 186,767 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 5, 2025 | marketbeat.com

2 Beaten-Down Stocks With Incredible Upside Potential

August 3, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month

August 2, 2025 | finance.yahoo.com

Recursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on Tuesday

August 1, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

July 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, KNSA, RXRX, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.42 +0.36 (+2.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$16.41 -0.01 (-0.06%)

As of 08/8/2025 07:27 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$32.15 -0.96 (-2.90%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$32.16 +0.01 (+0.02%)

As of 08/8/2025 06:24 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Prime Medicine NYSE:PRME

$3.79 +0.11 (+2.99%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.77 -0.02 (-0.53%)

As of 08/8/2025 07:59 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.36 -0.05 (-0.92%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.38 +0.02 (+0.47%)

As of 08/8/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time